Icon

SABRIL (nda020427)- (500MG)

VIGABATRIN LUNDBECK PHARMS LLC
500MG
No No
Expired 2014-Aug-21
None None
None No
SABRIL is indicated for the treatment of: • Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; SABRIL is not indicated as a first line agent • Infantile Spasms -monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss
9 0 8
Total Other Developers 10
Drugs with Suitability No
500MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** *** ****** ****** ******* ******* *********** **** **. **-*-*, ***** ** ***** ********** ******, *****, ********, *** ******, ***** (***) ***
****** ** ****** **. *****'* ************ ******* *********** ***-*** - ******* **** - **, ****** ** ******,**,**&**, ****** ** * ** ** & ** ** **, **************** ******* ***********(*),, **********, ****** ******* ******, ***** (***) ***
****** ****** ****** ****** ************ - ******* ******* *********** ** *******, ***** *******, *******, ****** (***) ***
****** ***** ************ ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ***** ****-**** ******** ***. *********** **** ****** ****, ********, **** (**) *****, ****** ****** (***) ***
****** ***** ***** *************** ******* ******* *** *********** **** **.***, **** **. *, ** ****** ****, ********, *************, ****** ******* ******, ***** (***) ***
****** ****** ***** **** ****** ****** ******* ******* *********** **** **. **/*, **, ** ** **, ***** ***, *** ***********, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.